share_log

12 Health Care Stocks Moving In Tuesday's After-Market Session

Benzinga Real-time News ·  Jan 17, 2023 16:32

Gainers

  • Lucid Diagnostics (NASDAQ:LUCD) shares moved upwards by 10.9% to $1.73 during Tuesday's after-market session. The market value of their outstanding shares is at $67.6 million.
  • Nymox Pharmaceutical (NASDAQ:NYMX) stock increased by 10.65% to $0.52. The company's market cap stands at $46.9 million.
  • Artelo Biosciences (NASDAQ:ARTL) shares increased by 9.17% to $3.77. The company's market cap stands at $10.7 million.
  • Regulus Therapeutics (NASDAQ:RGLS) stock rose 8.73% to $1.63. The market value of their outstanding shares is at $27.4 million.
  • Clearside Biomedical (NASDAQ:CLSD) shares increased by 7.38% to $1.6. The market value of their outstanding shares is at $96.3 million.
  • Intelligent Bio Solutions (NASDAQ:INBS) stock rose 5.51% to $0.28. The market value of their outstanding shares is at $5.2 million.

Losers

  • Celyad Oncology (NASDAQ:CYAD) stock decreased by 7.4% to $1.76 during Tuesday's after-market session. This security traded at a volume of 3.8 million shares come close, making up 43311.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $39.7 million.
  • Dermata Therapeutics (NASDAQ:DRMA) stock fell 6.9% to $0.27. The company's market cap stands at $3.3 million.
  • PLx Pharma (NASDAQ:PLXP) stock fell 6.64% to $0.23. The company's market cap stands at $6.5 million.
  • Fulcrum Therapeutics (NASDAQ:FULC) shares decreased by 5.94% to $13.16. The market value of their outstanding shares is at $684.9 million.
  • PAVmed (NASDAQ:PAVM) shares decreased by 5.59% to $0.6. The market value of their outstanding shares is at $56.2 million.
  • Olema Pharmaceuticals (NASDAQ:OLMA) shares fell 4.99% to $4.19. The company's market cap stands at $169.5 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment